Element Biosciences develops platforms that generate genetic, molecular and cellular data by reading the genetic code of organisms including humans, plants, animals and microbes. The company positions its technology to support precision medicine, disease research, agriculture and forensics by enabling genomic and multiomic insights. Led by CEO Molly He, Element has been building a commercial ecosystem of genomic and multiomic solutions. The company said it will use proceeds from the Series E to accelerate commercialization, expand globally, and advance its product roadmap across research, translational science and diagnostic applications. Financially, Element announced this Series E after raising $277M in a Series D in July 2024 and secured $175M from Samsung Electronics in the current round with additional undisclosed investors. No revenue or user metrics were disclosed in the article.

Total raised

$823M

Funding rounds

5

Latest round

Series E

Latest activity

Jun 2026